Amsino Medical Group, a prominent global provider of medical consumable devices, has successfully concluded a significant equity investment from Novo Tellus, a leading investment firm specializing in the global supply chain. This strategic partnership, which officially closed in June 2024, marks a renewed collaboration between the two entities, following their previous successful alliance from 2011 to 2017.

Dr. Richard Y. Lee, Chairman and CEO of Amsino Medical Group, expressed his enthusiasm about the renewed partnership: “We’re excited to renew a long-term partnership with Novo Tellus. Novo Tellus has proven itself as a growth partner for Amsino before, and shares our fundamental commitment to delivering dependable innovation and value to our customers around the world.”

The collaboration is set to enhance Amsino’s production facilities in the US and expand its supply chain to better meet customer demands. “We are already working with Novo Tellus to build Amsino into a next-generation global medical supplier. We’re expanding our production facilities in the US and growing our supply chain to deliver more solutions, closer to market, for our customers. We’re proud of the long-term relationships we have with healthcare customers around the world, and we’re investing in research and advanced manufacturing to bring better solutions to market over time,” added Dr. Lee.

Novo Tellus Managing Partner, Loke Wai San, highlighted the strategic value of the investment: “We’ve been long-term believers in Amsino’s approach of delivering critical medical consumables to valued customers around the world. Today, as the global supply chain shifts in response to economic and geopolitical changes, we’ve listened to the market, and we see great strategic opportunity with growing Amsino’s existing US production to serve more customers more deeply here in the domestic market.”

Robert Chen, Operating Partner, and Pei Shan Wong, Senior Vice President at Novo Tellus, emphasized the global vision of the partnership: “Amsino has always been a global company, and even as we grow our US operations in support of our US customers, we’re looking to expand Amsino’s global footprint and operations. The global supply chain now demands more of suppliers: more products, more manufacturing locations, greater availability, and a shorter supply chain. With its US headquarters, established branded offerings, and deep experience in US and Asia operations, Amsino is strategically positioned to grow into a leading supplier of diversified medical consumables worldwide.”

The all-equity investment from Novo Tellus underlines a debt-free approach to expanding Amsino’s capabilities and reach. Amsino Medical Group, headquartered in Pomona, USA, continues to offer a broad range of medical devices, such as urological, infusion therapy, and patient care products, solidifying its reputation as a reliable partner for healthcare providers globally.

  Amsino Medical Group, global healthcare market, global supply chain, Healthcare Innovation, medical consumables, medical consumables expansion, medical device supply, Novo Tellus, Novo Tellus investment